73 related articles for article (PubMed ID: 18972633)
1. [Chronic myeloid leukemia:specific characteristics and targeted therapy].
Nacinović-Duletić A
Lijec Vjesn; 2007 May; 129 Suppl 3():5-9. PubMed ID: 18972633
[No Abstract] [Full Text] [Related]
2. [Molecular therapy of chronic myeloid leukemia--a new era in the treatment of malignant diseases].
Deininger M; Niederwieser D
Med Klin (Munich); 2002 Jan; 97 Suppl 1():1. PubMed ID: 11831065
[No Abstract] [Full Text] [Related]
3. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
Dvorak P; Hruba M; Subrt I
Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
[No Abstract] [Full Text] [Related]
4. Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Messina A; Di Raimondo F
Leuk Res; 2009 Jun; 33(6):e17. PubMed ID: 19036439
[No Abstract] [Full Text] [Related]
5. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
6. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
Uchiyama M; Ikeda T
Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
[No Abstract] [Full Text] [Related]
7. Follow-up study of patients diagnosed with chronic myelogenous leukemia treated with STI 571 in Ecuador.
Paz-Y-Miño C; Arévalo M; Sánchez ME; Cañizares C; Leone PE
Arch Med Res; 2007 Apr; 38(3):364-5. PubMed ID: 17350491
[No Abstract] [Full Text] [Related]
8. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentation.
Gollard R; Wierda W; Trent J
J Clin Oncol; 2007 Oct; 25(29):4682-3. PubMed ID: 17925564
[No Abstract] [Full Text] [Related]
10. Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia.
Roos C; Stenke L; Ohm L; Widell S; Kumlin M; Lindgren JA; Tornhamre S
Br J Haematol; 2008 Sep; 142(6):992-5. PubMed ID: 18573108
[No Abstract] [Full Text] [Related]
11. Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
Jin J; Chen H; Cao L
Leuk Res; 2009 Jun; 33(6):e18-9. PubMed ID: 19108890
[No Abstract] [Full Text] [Related]
12. Unexpected leukocytosis in a preoperative patient.
McLaren BK; Muldoon R; Veillon DM; Nordberg ML; Weinberger B; Cotelingam JD
J La State Med Soc; 2002; 154(1):17-9. PubMed ID: 11892878
[No Abstract] [Full Text] [Related]
13. Chronic myeloid leukemia and ankylosing spondylitis.
Ben Abdelghani K; El Menaa M; Ben Abdelghani K; Souabni L; Belhadj S; Chekili S; Laatar A; Zakraoui L
Tunis Med; 2012 Dec; 90(12):901. PubMed ID: 23247779
[No Abstract] [Full Text] [Related]
14. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
15. Differentiation therapy as an effective strategy for the treatment of chronic myelogenous leukemia.
Moosavi MA; Yazdanparast R
Med Hypotheses; 2006; 67(6):1470-1. PubMed ID: 16919395
[No Abstract] [Full Text] [Related]
16. Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.
Bhagavathi S; Borromeo V; Desai H; Crisan D
Ann Clin Lab Sci; 2008; 38(4):405-9. PubMed ID: 18988937
[TBL] [Abstract][Full Text] [Related]
17. Presentation of childhood CML mimicking bone sarcoma.
Radhakrishnan S; Das P; Singh S; Kalita D; Gupta SD; Bakhshi S
Pediatr Blood Cancer; 2009 Jul; 52(7):901-2. PubMed ID: 19214978
[No Abstract] [Full Text] [Related]
18. Persistence of molecular remission throughout pregnancy in CML after imatinib.
Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
[No Abstract] [Full Text] [Related]
19. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
[Next] [New Search]
